{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:09:44Z","timestamp":1792080584854,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T00:00:00Z","timestamp":1297468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00213-011-2194-7","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T04:14:43Z","timestamp":1297397683000},"page":"85-90","source":"Crossref","is-referenced-by-count":67,"title":["A prospective open-label study of aripiprazole in fragile X syndrome"],"prefix":"10.1007","volume":"216","author":[{"given":"Craig A.","family":"Erickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Stigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan K.","family":"Wink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Mullett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,12]]},"reference":[{"key":"2194_CR1","first-page":"485","volume":"5","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 5:485\u2013491","journal-title":"Am J Ment Defic"},{"key":"2194_CR2","first-page":"89","volume":"4","author":"R Amaria","year":"2001","unstructured":"Amaria R, Billeisen L, Hagerman R (2001) Medication use in fragile X syndrome. Mental Health Asp Dev Dis 4:89\u201393","journal-title":"Mental Health Asp Dev Dis"},{"issue":"1","key":"2194_CR3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1352\/0895-8017(2001)106<0016:VIFAED>2.0.CO;2","volume":"106","author":"DB Bailey Jr","year":"2001","unstructured":"Bailey DB Jr, Hatton DD, Tassone F, Skinner M, Taylor AK (2001) Variability in FMRP and early development in males with fragile X syndrome. Am J Ment Retard 106(1):16\u201327","journal-title":"Am J Ment Retard"},{"issue":"16","key":"2194_CR4","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ajmg.a.32439","volume":"146A","author":"DB Bailey Jr","year":"2008","unstructured":"Bailey DB Jr, Raspa M, Olmsted M, Holiday DB (2008) Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 146A(16):2060\u20132069","journal-title":"Am J Med Genet A"},{"issue":"5","key":"2194_CR5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/cap.2006.16.525","volume":"16","author":"E Berry-Kravis","year":"2006","unstructured":"Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S et al (2006) Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 16(5):525\u2013540","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"2194_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/mrdd.20007","volume":"10","author":"E Berry-Kravis","year":"2004","unstructured":"Berry-Kravis E, Potanos K (2004) Psychopharmacology in fragile X syndrome\u2014present and future. Ment Retard Dev Disabil Res Rev 10(1):42\u201348","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"1","key":"2194_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302(1):381\u2013389","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2194_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1025014929212","volume":"33","author":"JN Constantino","year":"2003","unstructured":"Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL et al (2003) Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 33(4):427\u2013433","journal-title":"J Autism Dev Disord"},{"issue":"10","key":"2194_CR9","first-page":"80","volume":"5","author":"CA Erickson","year":"2006","unstructured":"Erickson CA, Stigler KA, Posey D, McDougle C (2006) Managing maladaptive behaviors in fragile X patients. Curr Psychiatry 5(10):80\u201392","journal-title":"Curr Psychiatry"},{"issue":"6","key":"2194_CR10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/14737175.5.6.713","volume":"5","author":"CA Erickson","year":"2005","unstructured":"Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2005) Risperidone in pervasive developmental disorders. Expert Rev Neurother 5(6):713\u2013719","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"2194_CR11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nurt.2010.04.001","volume":"7","author":"CA Erickson","year":"2010","unstructured":"Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 7(3):258\u2013263","journal-title":"Neurotherapeutics"},{"key":"2194_CR12","unstructured":"Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH."},{"issue":"1","key":"2194_CR13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1542\/peds.2008-0317","volume":"123","author":"RJ Hagerman","year":"2009","unstructured":"Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A et al (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123(1):378\u2013390","journal-title":"Pediatrics"},{"issue":"2","key":"2194_CR14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajmg.10216","volume":"108","author":"DD Hatton","year":"2002","unstructured":"Hatton DD, Hooper SR, Bailey DB, Skinner ML, Sullivan KM, Wheeler A (2002) Problem behavior in boys with fragile X syndrome. Am J Med Genet 108(2):105\u2013116","journal-title":"Am J Med Genet"},{"issue":"3","key":"2194_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441(3):137\u2013140","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2194_CR16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1025873925661","volume":"27","author":"C Lord","year":"1997","unstructured":"Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S et al (1997) Diagnosing autism: analyses of data from the autism diagnostic interview. J Autism Dev Disord 27(5):501\u2013517","journal-title":"J Autism Dev Disord"},{"issue":"11","key":"2194_CR17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48(11):1110\u20131119","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"2194_CR18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5):314\u2013321","journal-title":"N Engl J Med"},{"issue":"7","key":"2194_CR19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","volume":"55","author":"CJ McDougle","year":"1998","unstructured":"McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55(7):633\u2013641","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"2194_CR20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","volume":"124","author":"R Owen","year":"2009","unstructured":"Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6):1533\u20131540","journal-title":"Pediatrics"},{"key":"2194_CR21","volume-title":"Leiter international performance scale-revised","author":"G Roid","year":"1997","unstructured":"Roid G, Miller L (1997) Leiter international performance scale-revised. Stoelting Company, Wood Dale (Illinois)"},{"issue":"9","key":"2194_CR22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/01.chi.0000220854.79144.e7","volume":"45","author":"L Scahill","year":"2006","unstructured":"Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT et al (2006) Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 45(9):1114\u20131123","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"2194_CR23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8):1400\u20131411","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"2194_CR24","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I et al (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5):e634\u2013641","journal-title":"Pediatrics"},{"issue":"3","key":"2194_CR25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","volume":"19","author":"KA Stigler","year":"2009","unstructured":"Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ et al (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19(3):265\u2013274","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"2194_CR26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","volume":"14","author":"KA Stigler","year":"2004","unstructured":"Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14(3):455\u2013463","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2194_CR27","volume-title":"Wechsler Intelligence Scale for Children","author":"D Wechsler","year":"1999","unstructured":"Wechsler D (1999) Wechsler Intelligence Scale for Children, 3rd edn. Psychological Corporation, San Antonio (Texas)","edition":"3"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2194-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2194-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:12:20Z","timestamp":1558642340000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2194-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2194-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,12]]}}}